SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Filana Therapeutics Reports Q3 2026 Results and Business Update

The company said patient screening in its Phase 2a study of simufilam in TSC-related epilepsy is expected to begin by Q1 2.

FLNA

Story updates

01:15:22 PM UTC
SquawkNews
Filana Therapeutics reported a third-quarter 2026 net loss of $10.7 million, or $0.22 per share, and had $47.0 million in cash and cash equivalents at September 30. The company said the FDA lifted its clinical hold on simufilam for TSC-related epilepsy in September, with patient screening in a plan…

Related stories